CXCR2 and cancer: Pertinently, the CXCR2 and CXCR4 chemokine receptors are currently among the most promising GPCR targets in anti-cancer drug development, as they are aberrantly expressed in many tumors, where they exert potent proliferative, pro-survival, and pro-migratory effects [60, 61].